Recombinant Mouse TIGIT protein (His Tag)

种属

Mouse

纯度

>95 %, SDS-PAGE

标签

His Tag

生物活性

EC50: 16-65 ng/mL

Cat no : Eg0925

Print datasheet

Synonyms

TIGIT, Vstm3



产品信息

纯度 >95 %, SDS-PAGE
内毒素 <0.1 EU/μg protein, LAL method
生物活性 Immobilized Mouse TIGIT (His tag) at 1 μg/mL (100 μL/well) can bind Mouse CD155 (hFc tag) with a linear range of 16-65 ng/mL.
来源 HEK293-derived Mouse TIGIT protein Gly26-Thr143 (Accession# NP_001139797.1) with a His tag at the C-terminus.
基因ID 100043314
蛋白编号 NP_001139797.1
预测分子量 13.7 kDa
SDS-PAGE 15-25 kDa, reducing (R) conditions
组分 Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
复溶 Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
储存条件
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
运输条件 The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

背景信息

TIGIT (T-cell immunoreceptor with Ig and ITIM domains), also known as VSIG9 or VSTM3, is an immune receptor expressed on T cells, including Treg and memory subsets, as well as on NK cells. It contains an immunoglobulin variable domain, a transmembrane domain, and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT binds to poliovirus receptor (PVR, also called CD155) with high affinity, and also to PVRL2 (CD112) with lower affinity. The interaction of TIGIT with PVR on dendritic cells increases the secretion of IL-10 and decreases the secretion of proinflammatory cytokine and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells. TIGIT can inhibit NK cytotoxicity directly through its ITIM.

参考文献:

1.Xin Yu, et al. (2009). Nat Immunol. 10(1):48-57. 2.Noa Stanietsky, et al. (2009). Proc Natl Acad Sci U S A. 106(42):17858-63. 3.Joe-Marc Chauvin, et al. (2020). J Immunother Cancer. 8(2):e000957.